IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Track this case

Case overview

Case Number:

2:16-md-02724

Court:

Pennsylvania Eastern

Nature of Suit:

Other Statutes: Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

CYNTHIA M. RUFE

Firms

Companies

Government Agencies

Sectors & Industries:

January 03, 2019
AGs Blast Generic Cos.' Bid To Gag Price-Fixing Comments

Defending their right to comment publicly on multidistrict litigation and ongoing probes into alleged price-fixing by generic-drug companies, dozens of state attorneys general have told a Pennsylvania federal judge that a speech limitation sought by the drug companies would be unnecessary and unconstitutional.
January 01, 2019
Life Sciences Cases To Watch In 2019

The life sciences industry will be keeping an eye on courtrooms around the country in 2019, watching to see how the U.S. Supreme Court decides a legal battle over patent protection for drugs and monitoring the fallout from federal prosecutors' decision to spike a False Claims Act case. Here are seven cases life sciences attorneys say they'll be following in the coming year.
December 19, 2018
Generic-Drug Cos. Want AGs To Shut Up About Price-Fixing

Generic-drug companies facing multidistrict litigation and ongoing probes into alleged price-fixing are tired of hearing about them in the news, according to a brief filed in Pennsylvania federal court Tuesday that argues state attorneys general offices have violated legal and ethical requirements to keep mum.
November 15, 2018
Judge Won't Quash AGs' Subpoenas In Generic Pricing MDL

The New York and Connecticut attorneys general can keep sending subpoenas to drugmakers as part of their broader investigations into generic-drug price-fixing, a Pennsylvania federal judge has ruled, despite the drug companies’ concern the investigations were circumventing the discovery process for a sprawling multidistrict litigation.
November 05, 2018
Humana Seeks Case's Inclusion In Generic Price-Fixing MDL

Humana on Friday asked the Pennsylvania federal court overseeing the sprawling multidistrict litigation over generic drug prices to formally incorporate its action into the MDL, saying its claims target many of the same drugs that the group of states and proposed classes of drug buyers are targeting.
October 17, 2018
20 Drugmakers Must Face Generic Price-Fixing MDL

A Pennsylvania federal court has greenlighted the first round of multidistrict litigation accusing more than 20 generic-drug makers of conspiring to fix their prices, excusing only Teligent Inc. from the antitrust litigation.
September 26, 2018
McKesson Is Roped Into Generic-Drug Price-Fixing Row

McKesson Corp. earned billions of dollars by cooperating with an industrywide price-fixing conspiracy among generic-drug makers, according to a proposed class action Tuesday that appeared to be one of the first suits linking a drug distributor to multidistrict litigation over alleged drugmaker collusion.
January 03, 2018
Generics Buyers Fight To Keep 2 Drugs In Antitrust MDL

Direct purchaser plaintiffs in a large antitrust class action alleging price-fixing of a variety of generic drugs are pushing back against a motion to dismiss claims over two drugs, telling a Pennsylvania federal judge that the complaints contain more than enough of a basis to open discovery.
November 15, 2017
State AGs Want Separate Track In Generic Price-Fixing MDL

State attorneys general accusing 18 drug companies of conspiring to fix the prices of 15 generic drugs urged a Pennsylvania federal judge Tuesday to establish a separate government track within the broader multidistrict litigation, saying they can't yield authority to other entities such as private parties' lead counsel and their allegations are too broad to be litigated drug by drug.
October 31, 2017
State AGs Triple Size Of Generic Price-Fixing Litigation

The 46 attorneys general accusing six drug companies of conspiring to fix the price of two generic drugs said Tuesday they're asking a Pennsylvania federal court for permission to massively expand their suit by targeting 12 more drug companies, 13 more drugs, and Mylan and Emcure executives.

← Previous
…
4
5
6
7
8
9
10
11
12
Next →